Lv46
570 积分 2024-06-26 加入
First-line treatment for advanced NSCLC in older patients and those with poor performance status
1小时前
已完结
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
5天前
已完结
The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer
5天前
已关闭
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study
5天前
已完结
Efficacy, Safety, and Influence on Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1 Positive NSCLC: A Phase 2 Trial (EAST ENERGY)
5天前
已完结
Immune Checkpoint Inhibitors as First-line Treatment for Brain Metastases in Stage IV NSCLC Patients without Driver Mutations
7天前
已完结
Perioperative Nivolumab in Resectable Lung Cancer
15天前
已完结
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
15天前
已完结
Analysis of HYAL3 gene mutations in Chinese lung squamous cell carcinoma patients
27天前
已关闭
我国胸腺微创外科的机遇与挑战
27天前
已完结
皖公网安备34019202002308
